 Home > Active Ingredient News > Antitumor Therapy > ESMO Open: Connect or not?

ESMO Open: Connect or not?

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

uv treatment psoriasis

pylori treatment uptodate

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The COVID-19 pandemic has swept the world, affecting more than 180 million people, and has caused more than 4 million deaths so far

COVID-19 immunization priority should be vaccinated

In this study, between February 15 and March 2, 2021, 159 patients with solid tumors and 41 patients with hematological malignancies were recruited

All 200

The most frequently reported local adverse reaction is mild to moderate pain at the injection site

Figure 2: Local and systemic adverse events bnt162b2 reported within seven days after vaccination

Figure 2 Figure 2 Figure 2

A total of 7 serious adverse reactions were reported this time

Breast cancer thrombosis transient mild neurological disease myocardial infarction

Vaccine-induced antibody response and effectiveness of immune response

The geometric mean titers (GMT) of SARS-CoV-2 RBD-IgG antibody in patients with solid tumors receiving chemotherapy 28 days after booster vaccination were significantly lower than those of healthy controls (GMT were 2955.

However, compared with healthy controls, the percentage of high responders in the chemotherapy and hematology cohorts (55% and 29%, respectively) was significantly lower

The changes in the treatment cohort over time are significantly different from those in the healthy control group, mainly between baseline and 21 days after the initial vaccination, which indicates that the cancer patients undergoing treatment have a delayed antibody response

By analyzing the anti-S1 antibody response against the Wuhan SARS-CoV-2 wild-type strain and the in vitro 50% neutralization titer (NT50), this study will further evaluate the vaccine-induced humoral immune response

Among all patients who received booster vaccination, 52% of patients had at least one SARS-CoV-2 nucleic acid test between the initial and booster vaccination, and only two patients (both receiving targeted/hormonal therapy) tested positive.
1 case was asymptomatic and 1 case was moderate
.
Within 3 months after the booster dose , three cancer patients (two receiving targeted/hormonal therapy and one suffering from hematological malignancies) detected SARS-CoV- after the booster vaccination (17, 38 and 39 days later) 2 positive
.
The patients receiving hormone therapy developed an appropriate immune response (anti-rbd IgG titer 1825iu/mL) at 28 days after the booster vaccination, explaining their asymptomatic infection
.
Patients receiving rituximab did not show any signs of humoral immune response 28 days after the booster vaccination, which explains the two-week hospitalization of severe COVID-19 infection
.
Among all patients who received booster vaccination, 52% of patients had at least one SARS-CoV-2 nucleic acid test between the initial and booster vaccination, and only two patients (both receiving targeted/hormonal therapy) tested positive.
1 case was asymptomatic and 1 case was moderate
.
Within 3 months after the booster dose , three cancer patients (two receiving targeted/hormonal therapy, one suffering from hematological malignancies) detected SARS-CoV- after the booster vaccination (17, 38 and 39 days later) 2 positive
.
The patients receiving hormone therapy developed an appropriate immune response (anti-rbd IgG titer 1825iu/mL) at 28 days after the booster vaccination, explaining their asymptomatic infection
.
Patients receiving rituximab did not show any signs of humoral immune response 28 days after the booster vaccination, which explains the two-week hospitalization of severe COVID-19 infection
.
Among all patients who received booster vaccination, 52% of patients had at least one SARS-CoV-2 nucleic acid test between the initial and booster vaccination, and only two patients (both receiving targeted/hormonal therapy) tested positive.
1 case was asymptomatic and 1 case was moderate
.
Within 3 months after the booster dose, Three cancer patients (two received targeted/hormonal therapy and one had hematological malignancies) tested positive for SARS-CoV-2 after booster vaccination (17, 38 and 39 days later)
.
The patients receiving hormone therapy developed an appropriate immune response (anti-rbd IgG titer 1825iu/mL) at 28 days after the booster vaccination, explaining their asymptomatic infection
.
Patients receiving rituximab did not show any signs of humoral immune response 28 days after the booster vaccination, which explains the two-week hospitalization of severe COVID-19 infection
.
, Three cancer patients (two received targeted/hormonal therapy and one had hematological malignancies) tested positive for SARS-CoV-2 after booster vaccination (17, 38 and 39 days later)
.
The patients receiving hormone therapy developed an appropriate immune response (anti-rbd IgG titer 1825iu/mL) at 28 days after the booster vaccination, explaining their asymptomatic infection
.
Patients receiving rituximab did not show any signs of humoral immune response 28 days after the booster vaccination, which explains the two-week hospitalization of severe COVID-19 infection
.

This study shows that although actively treated cancer patients (including immunotherapy patients) tolerate the BNT162b2 COVID-19 vaccine well, some cancer patients still lack the ability to have an effective immune response, especially when receiving chemotherapy or rituximab Treatment-resistant patients
.
Therefore, under these circumstances, herd immunity and self-protection are of the utmost importance, and caregivers, family members and/or close contacts of these patients should be vaccinated as soon as possible
.
In addition, this study raises the issue of a third dose of vaccination to improve the immunity of cancer patients, as it has recently been demonstrated that this can significantly improve the immunogenicity of the BNT162b2 vaccine
.
This study shows that although actively treated cancer patients (including immunotherapy patients) tolerate the BNT162b2 COVID-19 vaccine well, some cancer patients still lack the ability to have an effective immune response, especially when receiving chemotherapy or rituximab Treatment-resistant patients
.
Therefore, under these circumstances, herd immunity and self-protection are of the utmost importance, and caregivers, family members and/or close contacts of these patients should be vaccinated as soon as possible
.
In addition, this study raises the issue of a third dose of vaccination to improve the immunity of cancer patients, as it has recently been demonstrated that this can significantly improve the immunogenicity of the BNT162b2 vaccine
.
This study shows that although actively treated cancer patients (including immunotherapy patients) tolerate the BNT162b2 COVID-19 vaccine well, some cancer patients still lack the ability to have an effective immune response, especially when receiving chemotherapy or rituximab Treatment-resistant patients
.
Therefore, under these circumstances, herd immunity and self-protection are of the utmost importance, and caregivers, family members and/or close contacts of these patients should be vaccinated as soon as possible
.
In addition, this study raises the issue of a third dose of vaccination to improve the immunity of cancer patients, as it has recently been demonstrated that this can significantly improve the immunogenicity of the BNT162b2 vaccine
.
This study shows that although actively treated cancer patients (including immunotherapy patients) tolerate the BNT162b2 COVID-19 vaccine well, some cancer patients still lack the ability to have an effective immune response, especially when receiving chemotherapy or rituximab Treatment-resistant patients
.
Therefore, under these circumstances, herd immunity and self-protection are of the utmost importance, and caregivers, family members and/or close contacts of these patients should be vaccinated as soon as possible
.
In addition, this study raises the issue of a third dose of vaccination to improve the immunity of cancer patients, as it has recently been demonstrated that this can significantly improve the immunogenicity of the BNT162b2 vaccine
.

In summary, the BNT162b2 vaccine is safe for cancer patients who are receiving anti-tumor therapy
.
However, the decrease in SARS-CoV-2 RBD-IgG antibody levels indicates a decrease in effectiveness.
Considering the increased risk of severe COVID-19 in cancer patients, this has important public health significance
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.